News

Fierce Pharma2h
Madrigal touts biomarker data in key MASH population as it works to grow Rezdiffra's reach
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
MyChesCo on MSN7h
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Asianet Newsable on MSN17h
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive ...
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential
We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.
Fierce Biotech5d
Roche launches fibrosis blood test for gauging liver disease severity
Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential
We recently published a list of Billionaire John Paulson’s 10 Stocks with Huge Upside Potential. In this article, we are ...
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...